A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Patients With Previously Untreated Chronic Lymphocytic Leukemia
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Patients With Previously Untreated Chronic Lymphocytic Leukemia
The purpose of this study is to investigate the efficacy and safety of fixed-duration sonrotoclax (also known as BGB-11417) plus zanubrutinib (also known as BGB-3111) (SZ) compared with fixed-duration of venetoclax plus acalabrutinib (AV) in participants with previously untreated chronic lymphocytic leukemia (CLL).
Inclusion Criteria:
Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
clinicaltrials@beonemed.com8778285568
Miami, Florida 33140, United States
Pittsburgh, Pennsylvania 15232-1309, United States
São Paulo, 05652-900, Brazil
Québec, Quebec G1J 1Z4, Canada
Chongqing, Chongqing Municipality 630014, China
Shanghai, Shanghai Municipality 200025, China
Chengdu, Sichuan 610071, China
Tianjin, Tianjin Municipality 300020, China
Hangzhou, Zhejiang 310002, China
PLZE, 323 00, Czechia
ClermontFerrand, 63100, France
Deggendorf, 94469, Germany
Sgravenhage, 2545 AA, Netherlands
Wroclaw, 50-367, Poland
Bucureti, 022328, Romania
ClujNapoca, 400015, Romania
SeochoGu, Seoul Teugbyeolsi 06591, South Korea
SeodaemunGu, Seoul Teugbyeolsi 03722, South Korea
SongpaGu, Seoul Teugbyeolsi 05505, South Korea
Bournemouth, BH7 7DW, United Kingdom